Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial

Authors :: Richard E. Pratley
Julio Rosenstock
Bernard Zinman
Mark A. Espeland
Yutaka Seino
Darren K. McGuire
Maria Weber
Odd Erik Johansen
Michaela Mattheus
Nikolaus Marx
Annett Keller
Knut Robert Andersen
Takashi Kadowaki
Source :: Diabetes, obesity and metabolism 23(2), 569-580 (2021). doi:10.1111/dom.14254, Diabetes, Obesity & Metabolism
Publication Year :: 2020
Publisher :: Wiley, 2020.
Abstract: Diabetes, obesity and metabolism 23(2), 569-580 (2021). doi:10.1111/dom.14254<br />Published by Wiley-Blackwell, Oxford [u.a.]

Subjects :: Adult
linagliptin
medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
030209 endocrinology & metabolism
Dipeptidyl peptidase-4 inhibitor
Type 2 diabetes
030204 cardiovascular system & hematology
Linagliptin
Lower risk
03 medical and health sciences
0302 clinical medicine
Endocrinology
Double-Blind Method
cardiovascular disease
Internal medicine
Diabetes mellitus
Internal Medicine
medicine
Clinical endpoint
Humans
Hypoglycemic Agents
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Aged
Aged, 80 and over
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
business.industry
clinical trial
DPP‐4 inhibitor
Original Articles
Middle Aged
medicine.disease
Glimepiride
Sulfonylurea Compounds
Treatment Outcome
Diabetes Mellitus, Type 2
sulphonylureas
Original Article
business
Mace
hypoglycaemia
medicine.drug

Full Text Access

Tools